Enterococcus faecalis Infective Endocarditis: Is It Time to Abandon Aminoglycosides?
Date
2013
Type:
Article
item.page.extent
item.page.accessRights
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.other
item.page.references
Abstract
Since the first description of enterococcal infective endocarditis (IE) in 1899 and the subsequent availability of antibiotics for the treatment of this life-threatening infection, clinicians have faced important challenges in the management of this disease Enterococci exhibit intrinsic antibiotic resistance (eg, to cephalosporins , clindamycin), are less susceptible to various antibiotics (eg, β-lactams) that are active against streptococci and staphylococci, and are often tolerant to compounds (penicillin) that normally have a bactericidal effect against other susceptible bacteria.The lack of efficacy of penicillin for many cases of enterococcal IE sparked interest in possible alternative therapies.
Description
item.page.coverage.spatial
item.page.sponsorship
Citation
Clinical Infectious Diseases, 2013, 56(9):1269–72
Keywords
Enterococcus faecalis, High-level resistance, Infective endocarditis, Aminoglycosides